

Special Issue

Novel Therapeutic Approaches in Neuroendocrine Tumors

Message from the Guest Editor

Neuroendocrine tumors (NETs) are a heterogeneous class of neoplasms arising from the diffuse neuroendocrine system that may occur at many different anatomical sites. Management of NETs represents a clinical challenge because of their late onset and absence of selective biomarkers. High-grade tumors are often treated with cytotoxic chemotherapy, while low-grade tumors are usually treated with somatostatin analogs as well as radio-conjugated somatostatin analogs. Although these approaches have proven effective in slowing tumor growth their efficacy is limited to specific patient populations. This Special Issue aims to address recent advances in the development of new therapeutic strategies for the treatment of NETs.

Guest Editor

Dr. Federica Campolo

Department of Experimental Medicine, "Sapienza" University of Rome,
Viale Regina Elena 324, 00161 Rome, Italy

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/156821

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)